Vialox
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Vialox is a pentapeptide in the neuromuscular relaxer family of topical cosmetic peptides, aimed at the same expression-line target as Argireline (acetyl Hexapeptide-3), SNAP-8, Syn-Ake, and Pentapeptide-18, but acting at a different point in the neuromuscular signal.
What does it do in my body?
Vialox competitively antagonizes the acetylcholine receptor at the post-synaptic membrane, reducing muscle depolarization and contraction. This is the same end goal as Syn-Ake but a different target site on the neuromuscular junction.
How can it help me?
- Where the science stands: Anecdotal: 0 studies, 0 human trials on the public profile
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data specific to Vialox was captured in the source profile. Family-wide read: topical delivery carries a benign safety record.
Regulatory status: Cosmetic-marketing-grade only — sold as an OTC topical ingredient, not an FDA-reviewed drug.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Topical-only cosmetic ingredient, formulated into leave-on serums. No specific concentration or use-frequency figure was captured in the source profile.
What should I avoid combining — and what's synergistic?
Vialox doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
A different target site on the same neuromuscular junction the other “topical Botox” peptides work on — same goal, thin public evidence.
| Class | Neuromuscular “Botox-like” relaxer — topical cosmetic peptide |
| Mechanism (one line) | Competitively antagonizes the acetylcholine receptor at the post-synaptic membrane → reduced muscle depolarization and contraction |
| Evidence base | Anecdotal: 0 studies, 0 human trials on the public profile |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
Vialox is a pentapeptide in the neuromuscular relaxer family of topical cosmetic peptides, aimed at the same expression-line target as Argireline (acetyl Hexapeptide-3), SNAP-8, Syn-Ake, and Pentapeptide-18, but acting at a different point in the neuromuscular signal.
How it works
Vialox competitively antagonizes the acetylcholine receptor at the post-synaptic membrane, reducing muscle depolarization and contraction. This is the same end goal as Syn-Ake but a different target site on the neuromuscular junction.
What the research shows
Public profile grade: Anecdotal — 0 studies, 0 human trials. OHM’s 0035 categorization pass keeps Vialox at Tier D / provisional (encyclopedia-only).
Real-world protocol
Topical-only cosmetic ingredient, formulated into leave-on serums. No specific concentration or use-frequency figure was captured in the source profile.
Side effects & management
No adverse-effect data specific to Vialox was captured in the source profile. Family-wide read: topical delivery carries a benign safety record.
Regulatory status
Cosmetic-marketing-grade only — sold as an OTC topical ingredient, not an FDA-reviewed drug.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier D / provisional (encyclopedia-only).
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Argireline (acetyl Hexapeptide-3) · SNAP-8 · Syn-Ake · Pentapeptide-18
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Anecdotal, 0 studies, 0 human trials.
- OHM tier/safety grading: Tier D / provisional (encyclopedia-only).
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Argireline (acetyl Hexapeptide-3) · SNAP-8 · Syn-Ake · Pentapeptide-18